Auf dieser Seite
JBIO Jade Biosciences, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 10, 2026
$14,12
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$8,3652-Wochen-Tief
$28,0052-Wochen-Hoch
Marktkapitalisierung (MRQ)
$897M
P/E
-4.4
EPS
$-3.19
Ihre Abzeichen
52W-Spanne
$8–$28
Analystenbewertung
STRONG BUY
Kursziel
$50
P/E
-4.4
ROE
-47.7%
Nettogewinnmarge
·
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
JBIO Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$14.12
Marktkapitalisierung (MRQ)
$897M
P/E
-4.4
EPS
$-3.19
ROE
-47.7%
52W-Spanne
$8–$28
JBIO Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 29. April 2025 | 1-for-35 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
EPS$-3.192021-12-31 → 2025-12-31
Freier Cashflow$-95M2021-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | JBIO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -4.45-Jahres-Durchschnitt ≈-205.6 | ≈-205.6 | · | · | |
| K/B (MRQ) | 2.05-Jahres-Durchschnitt ≈99.4 | ≈99.4 | 3.9 | Unterbewertet | |
| Price / FCF (Kurs / FCF) | -7.35-Jahres-Durchschnitt ≈-351.1 | ≈-351.1 | · | · | |
| Price / Cash Flow (Kurs / Cashflow) | -7.45-Jahres-Durchschnitt ≈-289.8 | ≈-289.8 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 2.15-Jahres-Durchschnitt ≈115.4 | ≈115.4 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | JBIO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| ROA | -60.3%5-Jahres-Durchschnitt ≈-48.7% | ≈-48.7% | -39.1% | Schwach | |
| ROE | -47.7%5-Jahres-Durchschnitt ≈-79.5% | ≈-79.5% | -45.9% | Im Einklang | |
| ROIC | -34.2%5-Jahres-Durchschnitt ≈-52.3% | ≈-52.3% | -59.1% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | JBIO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 14.95-Jahres-Durchschnitt ≈26.9 | ≈26.9 | 7.0 | Starke Liquidität | |
| Quick Ratio | 20.35-Jahres-Durchschnitt ≈26.0 | ≈26.0 | 1.5 | Starke Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Für diese Kennzahlengruppe sind noch keine Daten verfügbar
Noch nicht genügend Fundamentaldaten vorhanden, um diese Kennzahlengruppe zu berechnen.
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Dividenden Rendite, Ausschüttungsquote, Dividendenhistorie, 5-Jahres-CAGR
| Ex-Datum | Betrag | Währung | Rendite |
|---|---|---|---|
| Apr 29, 2025 | $2,40 | USD | ≈23.7% |
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-9.4%
Nächster Bericht
Nov 11, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 11, 2026 | $-0.76 | $-0.65 | -17.2% |
| 31. März 2026 | $-0.57 | $-0.49 | -15.8% | |
| 31. Dezember 2025 | $-0.59 | $-0.48 | -22.0% | |
| 30. September 2025 | $-0.48 | $-0.69 | 30.2% | |
| 30. Juni 2025 | $-0.86 | $-0.44 | -94.8% | |
| 31. März 2025 | $-3.15 | $-8.57 | 63.2% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $93M | $53M | $64M | $39M | $15M | $8M | |
| SG&A Expense | $20M | $21M | $17M | $15M | $8M | $949.0K | |
| Operating Expenses | $114M | $75M | $81M | $53M | $23M | $9M | |
| Operating Income | $-114M | $-75M | $-81M | $-53M | $-23M | $-9M | |
| Interest Expense | · | · | · | · | · | $75.0K | |
| Other Non-op | $-8.0K | $-19.0K | $-1.0K | $2M | $62.0K | $-722.0K | |
| Pretax Income | $-127M | $-70M | $-75M | $-51M | $-23M | $-10M | |
| Income Tax | $58.0K | $55.0K | $56.0K | $25.0K | $3.0K | · | |
| Net Income | $-127M | $-70M | $-76M | $-52M | $-23M | $-10M | |
| EPS (Basic) | $-3.19 | $-2.44 | $-2.87 | $-2.10 | $-1.87 | · | |
| EPS (Diluted) | $-3.19 | $-2.44 | $-2.87 | $-2.10 | $-1.87 | · | |
| Shares (Basic) | 31,359,958 | 28,582,194 | 26,331,630 | 24,472,104 | 12,293,629 | · | |
| Shares (Diluted) | 31,359,958 | 28,582,194 | 26,331,630 | 24,472,104 | 12,293,629 | · | |
| EBITDA | $-114M | $-75M | $-81M | $-53M | $-23M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $88M | $69M | $23M | $22M | $54M | $5M | |
| Short-term Investments | $248M | $0 | $99M | $107M | $113M | · | |
| Prepaid Expense | $13M | $268.0K | $2M | $2M | $7M | $103.0K | |
| Current Assets | $349M | $70M | $124M | $131M | $174M | $5M | |
| PP&E (Net) | $170.0K | · | $288.0K | $242.0K | $186.0K | $39.0K | |
| PP&E (Gross) | · | · | · | · | · | $40.0K | |
| Accum. Depreciation | · | · | · | · | · | $1.0K | |
| Other Non-current Assets | $69.0K | $3M | $2M | $3M | $302.0K | · | |
| Total Assets | $350M | $73M | $127M | $135M | $175M | $5M | |
| Accounts Payable | $2M | $1M | $2M | $3M | $1M | $618.0K | |
| Accrued Liabilities | $9M | $4M | · | · | · | · | |
| Current Liabilities | $17M | $12M | $18M | $8M | $3M | $2M | |
| Capital Leases | $724.0K | $0 | $255.0K | $705.0K | $382.0K | · | |
| Total Liabilities | $17M | $120M | $18M | $9M | $3M | $2M | |
| Common Stock | $5.0K | $1.0K | $3.0K | $2.0K | $2.0K | · | |
| Paid-in Capital | $507M | $179.0K | $273M | $215M | $209M | $63.0K | |
| Retained Earnings | $-174M | $-47M | $-163M | $-88M | $-36M | $-13M | |
| AOCI | $129.0K | $0 | $237.0K | $-466.0K | $-59.0K | · | |
| Stockholders' Equity | $333M | $-47M | $109M | $127M | $172M | $-13M | |
| Liabilities + Equity | $350M | $73M | $127M | $135M | $175M | $5M | |
| Shares Outstanding | 49,316,287 | 3,672,794 | 27,762,703 | 24,722,974 | 24,410,393 | 243,076 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $20M | $11M | $12M | $5M | $2M | $58.0K | |
| Deferred Tax | $-44.0K | · | · | · | · | · | |
| Operating Cash Flow | $-95M | $-71M | $-57M | $-39M | $-27M | $-8M | |
| CapEx | $196.0K | · | $142.0K | $195.0K | $181.0K | · | |
| Investing Cash Flow | $-247M | $56M | $12M | $7M | $-113M | · | |
| Stock Issued | · | $24M | $45M | · | $127M | · | |
| Net Stock Activity | · | $24M | $45M | · | $127M | · | |
| Financing Cash Flow | $361M | $25M | $46M | $396.0K | $190M | $9M | |
| Net Change in Cash | $19M | $10M | $1M | $-32M | $50M | $1M | |
| Free Cash Flow | $-95M | · | $-57M | $-39M | $-28M | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| ROA | -60.3% | -67.0% | -57.5% | -33.2% | -25.5% | · | |
| ROE | -47.7% | -233.8% | -64.2% | -38.8% | -13.0% | · | |
| ROIC | -34.2% | -97.7% | -74.4% | -42.0% | -13.4% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 21.1 | 20.9 | 7.0 | 16.9 | 68.4 | · | |
| Quick Ratio | 20.3 | 20.5 | 6.9 | 16.6 | 65.6 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.74 | $2.64 | $3.94 | $5.13 | $7.06 | · | |
| Cash Flow / Share | $-3.02 | $-2.49 | $-2.16 | $-1.60 | · | · | |
| Cash / Share | $1.79 | $1.16 | $0.85 | $0.91 | $2.22 | · | |
| EPS (TTM) | $-3.19 | $-2.44 | $-2.87 | $-2.10 | $-1.87 | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-127M | $-70M | $-76M | $-52M | $-23M | · | |
| Market Cap | $761M | $2.69B | $21.99B | $25.35B | $10.07B | · | |
| P/E | -4.8 | -38.0 | -276.0 | -488.3 | -220.7 | · | |
| P/B | 2.3 | 35.2 | 200.9 | 200.0 | 58.4 | · | |
| P / Tangible Book | 2.3 | · | 200.9 | 200.0 | 58.4 | · | |
| P / Cash Flow | -8.0 | -37.8 | -387.3 | -648.1 | -367.6 | · | |
| P / FCF | -8.0 | · | -386.3 | -644.8 | -365.2 | · | |
| Earnings Yield | -20.7% | -2.6% | -0.36% | -0.20% | -0.45% | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $50M | $36M | $29M | $22M | $23M | $20M | $-2M | $14M | $21M | $20M | $18M | $17M | $16M | $13M | $12M | $11M | |
| SG&A Expense | $9M | $7M | $6M | $5M | $5M | $3M | $11M | $1M | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $3M | |
| Operating Expenses | $59M | $43M | $55M | $27M | $28M | $23M | $9M | $15M | $26M | $25M | $22M | $21M | $20M | $18M | $16M | $14M | |
| Operating Income | $-59M | $-43M | $-55M | $-27M | $-28M | $-23M | $-9M | $-15M | $-26M | $-25M | $-22M | $-21M | $-20M | $-18M | $-16M | $-14M | |
| Other Non-op | $-62.0K | $-9.0K | $4M | $-28.0K | $0 | $0 | $-1M | $0 | $1M | $-3.0K | $-2M | $1.0K | $1M | $1M | $2M | $4.0K | |
| Pretax Income | $-56M | $-40M | · | · | $-32M | $-38M | · | · | · | · | · | · | · | · | · | · | |
| Income Tax | $15.0K | $16.0K | $58.0K | $0 | $0 | · | · | $0 | · | · | · | · | · | · | · | · | |
| Net Income | $-56M | $-40M | $-32M | $-25M | $-32M | $-38M | $-5M | $-16M | $-25M | $-23M | $-20M | $-20M | $-19M | $-17M | $-15M | $-14M | |
| EPS (Basic) | $-0.76 | $-0.57 | $-1.76 | $-0.48 | $-0.86 | $-12.10 | $4.41 | $-5.16 | $-0.86 | $-0.83 | $-0.73 | $-0.71 | $-0.76 | $-0.67 | $-0.60 | $-0.56 | |
| EPS (Diluted) | $-0.76 | $-0.57 | $-1.76 | $-0.48 | $-0.86 | $-12.10 | $4.41 | $-5.16 | $-0.86 | $-0.83 | $-0.73 | $-0.71 | $-0.76 | $-0.67 | $-0.60 | $-0.56 | |
| Shares (Basic) | 61,050,775 | 57,777,165 | · | 39,584,489 | 28,431,158 | 3,155,500 | · | 3,155,500 | 28,756,043 | 27,795,827 | · | 27,640,542 | 25,166,505 | 24,777,847 | · | 24,454,786 | |
| Shares (Diluted) | 61,050,775 | 57,777,165 | · | 39,584,489 | 28,431,158 | 3,155,500 | · | 3,155,500 | 28,756,043 | 27,795,827 | · | 27,640,542 | 25,166,505 | 24,777,847 | · | 24,454,786 | |
| EBITDA | $-59M | $-43M | · | $-27M | $-28M | $-3M | · | $-17M | $-26M | $-25M | · | $-21M | $-20M | $-18M | · | $-14M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $107M | $55M | $88M | $50M | $221M | $44M | $34M | $31M | $31M | $9M | $23M | $32M | $61M | $27M | $22M | $22M | |
| Short-term Investments | $354M | $256M | $248M | $149M | · | $32M | $45M | $58M | $73M | $90M | $99M | $103M | $89M | $92M | $107M | $120M | |
| Prepaid Expense | $10M | $7M | $13M | $2M | $2M | $1M | $1M | $2M | $7M | $4M | $2M | $2M | $2M | $2M | $2M | $3M | |
| Current Assets | $471M | $319M | $349M | $201M | $223M | $77M | $80M | $91M | $111M | $103M | $124M | $138M | $152M | $121M | $131M | $145M | |
| PP&E (Net) | $144.0K | $157.0K | $170.0K | $176.0K | $147.0K | $2.0K | $6.0K | $14.0K | $232.0K | $260.0K | $288.0K | $316.0K | $245.0K | $267.0K | $242.0K | $330.0K | |
| Other Non-current Assets | $69.0K | $69.0K | $69.0K | $174.0K | $60.0K | · | · | $81.0K | $81.0K | $3M | $2M | $2M | $2M | $3M | $3M | $1M | |
| Total Assets | $472M | $319M | $350M | $202M | $224M | $78M | $80M | $91M | $112M | $107M | $127M | $141M | $156M | $124M | $135M | $148M | |
| Accounts Payable | $7M | $4M | $2M | $1M | $8M | $69.0K | $224.0K | $908.0K | $4M | $3M | $2M | $4M | $6M | $5M | $3M | $5M | |
| Accrued Liabilities | $15M | $15M | $9M | $14M | $8M | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $32M | $22M | $17M | $22M | $22M | $2M | $4M | $10M | $17M | $16M | $18M | $15M | $13M | $11M | $8M | $8M | |
| Capital Leases | $628.0K | $679.0K | $724.0K | $747.0K | $792.0K | · | · | $81.0K | $206.0K | $329.0K | $255.0K | $358.0K | $476.0K | $591.0K | $705.0K | $800.0K | |
| Total Liabilities | $32M | $23M | $17M | $23M | $22M | $2M | $4M | $10M | $17M | $16M | $18M | $15M | $14M | $11M | $9M | $9M | |
| Common Stock | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | $2.0K | |
| Paid-in Capital | $711M | $512M | $507M | $322M | $319M | $311M | $309M | $308M | $306M | $278M | $273M | $269M | $266M | $218M | $215M | $213M | |
| Retained Earnings | $-271M | $-215M | $-174M | $-142M | $-117M | $-236M | $-233M | $-228M | $-211M | $-187M | $-163M | $-143M | $-123M | $-104M | $-88M | $-73M | |
| AOCI | $-660.0K | $-342.0K | $129.0K | $29.0K | $-24.0K | $50.0K | $105.0K | $224.0K | $-83.0K | $-33.0K | $237.0K | $-195.0K | $-223.0K | $-201.0K | $-466.0K | $-771.0K | |
| Stockholders' Equity | $440M | $296M | $333M | $179M | $202M | $75M | $76M | $80M | $94M | $91M | $109M | $126M | $142M | $113M | $127M | $139M | |
| Liabilities + Equity | $472M | $319M | $350M | $202M | $224M | $78M | $80M | $91M | $112M | $107M | $127M | $141M | $156M | $124M | $135M | $148M | |
| Shares Outstanding | 63,556,065 | 49,345,967 | 49,316,287 | 32,626,730 | 32,626,730 | 28,985,019 | 28,985,019 | 28,867,711 | 28,854,750 | 27,898,761 | 27,762,703 | 27,653,187 | 27,601,098 | 24,816,940 | 24,722,974 | 24,506,390 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $14M | $7M | $11M | $4M | $4M | $2M | $3M | $27.0K | $4M | $4M | $3M | $3M | $3M | $2M | $2M | $1M | |
| Operating Cash Flow | $-44M | $-24M | $-34M | $-22M | $-37M | $-19M | $-11M | $-7M | $-20M | $-24M | $-15M | $-16M | $-15M | $-11M | $-15M | $-10M | |
| CapEx | · | · | $3.0K | $57.0K | · | · | · | · | · | · | $64.0K | $32.0K | $30.0K | $16.0K | $4.0K | $33.0K | |
| Investing Cash Flow | $-98M | $-8M | $-98M | $-149M | $-13M | $13M | $13M | $0 | $18M | $9M | $6M | $-13M | $4M | $15M | $14M | $5M | |
| Stock Issued | · | · | · | · | · | · | $307.0K | $0 | · | · | $0 | $0 | · | · | · | · | |
| Financing Cash Flow | $194M | $-795.0K | $170M | $0 | $191M | $-700.0K | $554.0K | $95M | $24M | $471.0K | $463.0K | $20.0K | $45M | $223.0K | $357.0K | $37.0K | |
| Net Change in Cash | $52M | $-33M | $38M | $-171M | $141M | $-19M | $3M | $88M | $22M | $-14M | $-9M | $-29M | $34M | $4M | $-22.0K | $-5M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-11M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -16.0% | -20.3% | · | -17.2% | -19.1% | -2.7% | · | -14.0% | -18.5% | -20.1% | · | -13.6% | -12.2% | -11.3% | · | -8.2% | |
| ROE | -17.4% | -21.7% | · | -19.4% | -21.7% | -3.0% | · | -15.8% | -21.0% | -22.7% | · | -14.8% | -13.0% | -12.0% | · | -8.5% | |
| ROIC | -13.4% | -14.7% | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.9 | 14.3 | · | 9.0 | 10.3 | 32.0 | · | 8.8 | 6.5 | 6.7 | · | 9.3 | 11.5 | 11.3 | · | 18.8 | |
| Quick Ratio | 14.6 | 14.0 | · | 8.9 | 10.2 | 31.5 | · | 8.6 | 6.1 | 6.4 | · | 9.2 | 11.3 | 11.2 | · | 18.5 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.92 | $6.01 | · | $5.50 | $6.18 | $2.59 | · | $2.79 | $3.27 | $3.26 | · | $4.55 | $5.14 | $4.56 | · | $5.68 | |
| Cash Flow / Share | · | $-0.42 | · | · | · | $-0.08 | · | · | · | $-0.85 | · | · | · | $-0.46 | · | · | |
| Cash / Share | $1.69 | $1.12 | · | $1.54 | $6.77 | $1.53 | · | $1.08 | $1.08 | $0.33 | · | $1.16 | $2.21 | $1.07 | · | $0.91 | |
| EPS (TTM) | $-3.57 | $-3.67 | · | $-9.03 | $-13.71 | $-13.71 | · | $-7.58 | $-3.13 | $-3.03 | · | $-2.74 | $-2.59 | $-2.32 | · | $-1.57 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-153M | $-130M | · | $-101M | $-92M | $-85M | · | $-85M | $-88M | $-82M | · | $-70M | $-64M | $-57M | · | $-45M | |
| Market Cap | $1.41B | $693M | · | $282M | $326M | $2.55B | · | $2.11B | $1.68B | $28.87B | · | $13.13B | $16.57B | $17.52B | · | $14.22B | |
| P/E | -6.2 | -3.8 | · | -1.0 | -0.7 | -6.4 | · | -9.7 | -18.6 | -341.6 | · | -173.3 | -231.8 | -304.3 | · | -369.6 | |
| P/B | 3.2 | 2.3 | · | 1.6 | 1.6 | 33.9 | · | 26.2 | 17.8 | 317.6 | · | 104.5 | 116.7 | 154.9 | · | 102.2 | |
| P / Tangible Book | 3.2 | 2.3 | · | 1.6 | 1.6 | 33.9 | · | 26.2 | 17.8 | 317.6 | · | 104.5 | 116.7 | 154.9 | · | 102.2 | |
| P / Cash Flow | · | -28.8 | · | · | · | -1069.4 | · | · | · | -1219.7 | · | · | · | -1533.6 | · | · | |
| Earnings Yield | -16.1% | -26.1% | · | -104.6% | -137.2% | -15.6% | · | -10.4% | -5.4% | -0.29% | · | -0.58% | -0.43% | -0.33% | · | -0.27% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Nettoergebnis | $-127M | $-70M | $-76M | $-52M | $-23M |
| Verwässerte EPS | $-3.19 | $-2.44 | $-2.87 | $-2.10 | $-1.87 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 21.1 | 20.9 | 7.0 | 16.9 | 68.4 |
| Quick Ratio | 20.3 | 20.5 | 6.9 | 16.6 | 65.6 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-95M | · | $-57M | $-39M | $-28M |
Institutionelle Eigentümer (13F) 159 Einreicher · $1.6B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
159
Gehaltener Wert
$1.6B
Neue Positionen
52
Geschlossene Positionen
16
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 52 (+18 vs. Vorquartal) | 16 (+5 vs. Vorquartal) | 61 (+24 vs. Vorquartal) | 24 (-8 vs. Vorquartal) | +16.8M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| FMR LLC | $202.799.207 | 9.126.877 | 13,07% | Aktien |
| Fairmount Funds Management LLC | $101.178.637 | 4.553.494 | 6,52% | Aktien |
| RA CAPITAL MANAGEMENT, L.P. | $81.571.464 | 3.671.083 | 5,26% | Aktien |
| Venrock Adviser, LLC | $71.556.488 | 3.220.364 | 4,61% | Aktien |
| Bellevue Group AG | $67.948.671 | 3.057.996 | 4,38% | Aktien |
| Paradigm Biocapital Advisors LP | $63.491.539 | 2.857.405 | 4,09% | Aktien |
| BlackRock, Inc. | $62.248.241 | 2.801.451 | 4,01% | Aktien |
| FRANKLIN RESOURCES INC | $62.040.028 | 2.792.080 | 4,00% | Aktien |
| STATE STREET CORP | $51.890.033 | 2.335.285 | 3,34% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $49.878.856 | 2.244.773 | 3,21% | Aktien |
| JANUS HENDERSON GROUP PLC | $43.557.008 | 3.105.669 | 2,81% | Aktien |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $42.458.243 | 1.910.812 | 2,74% | Aktien |
| Polar Capital Holdings Plc | $41.039.940 | 1.846.982 | 2,64% | Aktien |
| Avidity Partners Management LP | $37.789.732 | 1.700.708 | 2,43% | Aktien |
| Remedium Capital Partners, LLC | $35.057.605 | 1.577.750 | 2,26% | Aktien |
| Soleus Capital Management, L.P. | $34.456.332 | 1.550.690 | 2,22% | Aktien |
| JPMORGAN CHASE & CO | $32.613.997 | 1.475.079 | 2,10% | Aktien |
| VANGUARD GROUP INC | $32.337.685 | 2.095.767 | 2,08% | Aktien |
| BAKER BROS. ADVISORS LP | $27.340.066 | 1.230.426 | 1,76% | Aktien |
| Logos Global Management LP | $24.997.500 | 1.125.000 | 1,61% | Aktien |
| Versant Venture Management, LLC | $22.037.418 | 991.783 | 1,42% | Aktien |
| ACORN CAPITAL ADVISORS, LLC | $21.925.807 | 986.760 | 1,41% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $21.896.658 | 985.178 | 1,41% | Aktien |
| CITADEL ADVISORS LLC | $20.651.423 | 929.407 | 1,33% | Aktien |
| Foresite Capital Management VI LLC | $19.701.741 | 886.667 | 1,27% | Aktien |
| Balyasny Asset Management L.P. | $19.525.292 | 878.726 | 1,26% | Aktien |
| Affinity Asset Advisors, LLC | $18.672.577 | 840.350 | 1,20% | Aktien |
| SAMSARA BIOCAPITAL, LLC | $16.359.186 | 736.237 | 1,05% | Aktien |
| GOLDMAN SACHS GROUP INC | $16.336.678 | 735.224 | 1,05% | Aktien |
| Pictet Asset Management Holding SA | $16.304.325 | 733.768 | 1,05% | Aktien |
| Aberdeen Group plc | $13.801.020 | 621.108 | 0,89% | Aktien |
| MARSHALL WACE, LLP | $13.015.609 | 585.761 | 0,84% | Aktien |
| BANK OF AMERICA CORP /DE/ | $10.820.140 | 486.955 | 0,70% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $10.255.152 | 461.528 | 0,66% | Aktien |
| Blackstone Inc. | $9.672.810 | 435.320 | 0,62% | Aktien |
| Ikarian Capital, LLC | $9.495.694 | 427.349 | 0,61% | Aktien |
| Walleye Capital LLC | $8.116.344 | 365.272 | 0,52% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $6.989.257 | 314.548 | 0,45% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $6.774.145 | 304.867 | 0,44% | Aktien |
| NORTHERN TRUST CORP | $6.556.700 | 295.081 | 0,42% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $4.825.229 | 217.157 | 0,31% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $4.431.312 | 199.429 | 0,29% | Aktien |
| Jump Financial, LLC | $3.838.439 | 172.747 | 0,25% | Aktien |
| Point72 Asset Management, L.P. | $3.715.273 | 167.204 | 0,24% | Aktien |
| Russell Investments Group, Ltd. | $3.623.746 | 163.084 | 0,23% | Aktien |
| Opaleye Management Inc. | $3.221.900 | 145.000 | 0,21% | Aktien |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $3.114.989 | 140.886 | 0,20% | Aktien |
| UBS Group AG | $2.834.761 | 127.577 | 0,18% | Aktien |
| MORGAN STANLEY | $2.766.679 | 124.513 | 0,18% | Aktien |
| Quantinno Capital Management LP | $2.548.990 | 114.716 | 0,16% | Aktien |
Aktivisten & 5%+-Eigentümer 5 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest IV L.P., Peter Evan Harwin, Tomas Kiselak ×3 Einreichungen | 9. Juni 2026 | 19,99% | Änderung | · | SEC |
| Sofinnova Venture Partners X, L.P. ("SVP X"), Sofinnova Management X, L.P. ("SM X LP"), Sofinnova Management X-A, L.L.C. ("SM X LLC"), Dr. James I. Healy ("Healy"), Dr. Maha Katabi ("Katabi") | 5. März 2026 | 0,30% | Änderung | Passive Anlage | SEC |
| RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P. ×5 Einreichungen | 30. April 2025 | 4,10% | Änderung | · | SEC |
| Atlas Venture Fund XII, L.P., Atlas Venture Associates XII, L.P., Atlas Venture Associates XII, LLC ×5 Einreichungen | 30. April 2025 | 0,20% | Änderung | M&A / Verkauf | SEC |
| Sofinnova Venture Partners X, L.P. (“SVP X”), Sofinnova Management X, L.P. (“SM X LP”), Sofinnova Management X-A, L.L.C. (“SM X LLC”), Dr. James I. Healy (“Healy”), Dr. Maha Katabi (“Katabi”) ×3 Einreichungen | 20. Februar 2024 | · | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 24 Insider · 11 Führungskräfte · 14 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Tom Frohlich | Chief Executive Officer | 12. Februar 2026 A | 86.331 | 0 | 0 | $0 |
| Timothy P Noyes | CHIEF EXECUTIVE OFFICER | 16. Mai 2024 M | 0 | 0 | 0 | $0 |
| Bradford D. Dahms | Chief Financial Officer | 12. Februar 2026 A | 37.813 | 0 | 0 | $0 |
| George A Eldridge | Officer Title: Chief Financial Officer and Treasurer | 14. Juni 2024 M | 5.022 | 0 | 0 | $0 |
| Benjamin T Dake | Officer Title: President, Chief Operating Officer and Secretary | 1. August 2024 M | 14.252 | 0 | 0 | $0 |
| Elizabeth Balta | Chief Legal Officer and Corporate Secretary | 12. Februar 2026 A | 28.125 | 0 | 0 | $0 |
| Andrew James King | Chief Scientific Officer & Head of Research and Development | 12. Februar 2026 A | 386.113 | 0 | 0 | $0 |
| Marinus Verwijs | CHIEF TECHNICAL OFFICER | 14. Juni 2024 M | 0 | 0 | 0 | $0 |
| Hunter Gillies | CHIEF MEDICAL OFFICER | 13. Juni 2024 M | 5.602 | 0 | 0 | $0 |
| Ralph Niven | CHIEF SCIENTIFIC OFFICER | 5. Februar 2024 M | 1.609 | 0 | 0 | $0 |
| Timothy Pigot | CHIEF COMMERCIAL OFFICER | 22. Januar 2024 A | · | 0 | 0 | $0 |
| Mark Eisner | Direktor | 25. Juni 2026 A | · | 0 | 0 | $0 |
| Christopher W. Cain | Direktor | 9. Juni 2026 A | · | 0 | 0 | $0 |
| Lawrence Otto Klein | Direktor | 9. Juni 2026 A | · | 0 | 0 | $0 |
| Erin Lavelle | Direktor | 9. Juni 2026 A | · | 0 | 0 | $0 |
| Eric Dobmeier | Direktor | 9. Juni 2026 A | · | 0 | 0 | $0 |
| David S. Grayzel | Direktor | 5. Juni 2024 A | 14.502 | 0 | 0 | $0 |
| Dr. Maha Katabi | Direktor | 5. Juni 2024 A | 3.758.686 | 0 | 0 | $0 |
| Joshua Resnick | Direktor | 5. Juni 2024 A | · | 0 | 0 | $0 |
| Habib J Dable | Direktor | 5. Juni 2024 A | · | 0 | 0 | $0 |
| Allison Dorval | Direktor | 5. Juni 2024 A | · | 0 | 0 | $0 |
| Mark T Iwicki | Direktor | 5. Juni 2024 A | · | 0 | 0 | $0 |
| Donald J Santel | Direktor | 5. Juni 2024 A | · | 0 | 0 | $0 |
| Atlas Venture Fund XII, L.P. | 10%-Eigentümer | 15. Juli 2022 J | 2.327.909 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 19 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,86% | 20.261 NS | 31. Juli 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,21% | 52.113 NS | 31. Juli 2026 | N-PORT |
| IWC · iShares Trust | 0,15% | 110.135 SH | 11. September 2026 | Täglich |
| FFSM · FIDELITY COVINGTON TRUST | 0,12% | 93.021 NS | 31. Juli 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,12% | 111.509 SH | 19. August 2026 | Täglich |
| PWS · Pacer Funds Trust | 0,06% | 712 NS | 31. Juli 2026 | N-PORT |
| IWO · iShares Trust | 0,04% | 305.709 SH | 11. September 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 34.886 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,02% | 836.516 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 187.416 SH | 19. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 19.767 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 489.225 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,01% | 124.984 SH | 19. August 2026 | Täglich |
| WSML · iShares Trust | 0,01% | 2.568 SH | 11. September 2026 | Täglich |
| ITOT · iShares Trust | 0,00% | 71.131 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 15.055 SH | 9. September 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.699.343 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.733 SH | 19. August 2026 | Täglich |
| ISCB · iShares Trust | · | 2.353 SH | 11. September 2026 | Täglich |
JBIO Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 17 Analysten
KAUF
Median-Ziel
$47.00
+232,9%
8 47,1%
Starker Kauf
8 47,1%
Kauf
1 5,9%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
8 Analysten · 2026-10-02Mittelwert-Ziel $50.12 +255,0%
← Unter allen Zielen
Aktueller Preis $14.12
Tief$40.00
Mittelwert$50.12
Hoch$77.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| JBIO | $761M | -4.8 | · | · | -47.7% | · |
| KURA | $913M | -3.3 | 25.2% | -413.0% | -116.2% | · |
| CGEM | $624M | -3.2 | · | · | -44.0% | · |
| CRVS | $575M | -14.5 | · | · | -21.6% | · |
| GLUE | $1.03B | · | 63.5% | -31.2% | -15.4% | · |
| RIGL | $784M | 2.2 | 64.1% | 124.7% | 155.1% | · |
| SANA | $1.09B | -4.2 | · | · | -172.3% | · |
| ARDX | $1.42B | -22.4 | 22.1% | -15.1% | -40.2% | · |
| OBX | · | · | · | · | · | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 10, 2026